|
1）「喘息予防・管理ガイドライン2009」作成委員，作成. 日本アレルギー学会 喘息ガイドライン専門部, 監修．喘息予防・管理ガイドライン2009. 東京: 協和企画；2009
|
|
|
|
|
2）Global initiative for asthma. Global strategy for asthma management and prevention. Revised 2014 www.ginaasthma.org
|
|
|
|
|
|
3）Barnes PJ. Targeting the epigenome in the treatment of asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2009; 6: 693-6
|
|
|
|
|
4）Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Asthma control study. Am J Respir Crit Care Med. 2004; 170: 836-44
|
|
|
|
|
|
5）Pavord ID, Jeffery PK, Qiu Y, et al. Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol. J Allergy Clin Immunol. 2009; 123: 1083-9
|
|
|
|
|
|
6）Wessler I, Kirkpatrick CJ. Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans. Br J Pharmacol. 2008; 154: 1558-71
|
|
|
|
|
|
7）Proskocil B, Sekhon HS, Jia Y, et al. Acetylcholine is an autocrine or paracrine hormone synthesized and secreted by airway bronchial epithelial cells. Endocrinology. 2004; 145: 2498-506
|
|
|
|
|
|
8）Gosens R, Zaagsma J, Meurs H, et al. Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir Res. 2006; 7: 73
|
|
|
|
|
|
9）Belmonte KE. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005; 2: 297-304
|
|
|
|
|
|
10）Jacoby D , Gleich GJ, Fryer AD. Human eosinophil major basic protein is an endogenous allosteric antagonist at the inhibitory muscarinic M2 receptor. J Clin Invest. 1993; 91: 1314-8
|
|
|
|
|
|
11）Alagha K, Palot A, Sofalvi T, et al. Long-acting muscarinic receptor antagonists for the treatment of chronic airway disease. Ther Adv Chronic Dis. 2014; 5: 85-98
|
|
|
|
|
|
12）Ikeda T, Anisuzzaman AS, Yoshiki H, et al. Regional quantification of muscarinic acetylcholine receptors andβ-adrenoceptors in human airways. Br J Pharmacol. 2012; 166: 1804-14
|
|
|
|
|
|
13）Barnes PJ. Distribution of receptor targets in the lung. Proc Am Thorac Soc. 2004; 1: 345-51
|
|
|
|
|
|
14）Roux E , Molimard M, Savineau JP, et al. Muscarinic stimulation of airway smooth muscle cells. Gen Pharmacol. 1998; 31: 349-56
|
|
|
|
|
|
15）O’Connor BJ, Towse LJ, Barnes PJ. et al. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. Am J Respir Crit Care Med. 1996; 154: 876-80
|
|
|
|
|
|
16）Ohta S , Oda N, Yokoe T, et al. Effect of tiotropium bromide on airway inflammation and remodelling in a mouse model of asthma. Clin Exp Allergy. 2010; 40: 1266-75
|
|
|
|
|
|
17）Bosnjak B, Tilp C, Tomsic C, et al. Tiotropium bromide inhibits relapsing allergic asthma in BALB/c mice. Pul Pharmacol Ther. 2014; 27: 44-51
|
|
|
|
|
|
18）Grainge CL, Lau LC, Ward JA, et al. Effect of bronchoconstriction on airway remodeling in asthma. N Eng J Med. 2011; 364: 2006-15
|
|
|
|
|
|
19）Gosens R, Bos IS, Zaagsma J, et al. Protective effects of tiotropium bromide in the progression of airway smooth muscle remodeling. Am J Respir Crit Care Med. 2005; 171: 1096-102
|
|
|
|
|
|
20）Bos IS, Gosens R, Zuidhof AB, et al. Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison. Eur Respir J. 2007; 30: 653-61
|
|
|
|
|
|
21）平田一人. 気管支喘息における抗コリン薬の意義. 日本呼吸管理学会. 2006; 15: 605-11
|
|
|
|
|
|
22）Iwamoto H, Yokoyama A, Shiota N, et al. Tiotropium bromide is effective for severe asthma with noneosinophilic phenotype. Eur Respir J. 2008; 31: 1379-82
|
|
|
|
|
|
23）Park HW, Yang MS, Park CS, et al. Additive role of tiotropium in severe asthmatics and Arg16Gly in ADRB2 as a potential marker to predict response. Allergy. 2009; 64: 778-83
|
|
|
|
|
|
24）野上裕子，本荘 哲, 岩永知秋. 非発作時に閉塞性換気障害を呈する気管支喘息患者に対する吸入抗コリン薬の長期効果. アレルギー. 2012; 61: 1675-82
|
|
|
|
|
25）Fardon T , Haggart K, Lee DK, et al. A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma. Respir Med. 2007; 101: 1218-28
|
|
|
|
|
|
26）Magnussen H, Bugnas B, van Noord J, et al. Improvements with tiotropium in COPD patients with concomitant asthma. Respir Med. 2008; 102: 50-6
|
|
|
|
|
|
27）Peters SP, Kunselman SJ, Icitovic N, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Eng J Med. 2010; 363: 1715-26
|
|
|
|
|
|
28）Bateman ED, Kornmann O, Schmidt P, et al. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. J Allergy Clin Immunol. 2011; 128: 315-22
|
|
|
|
|
|
29）Kerstjens HA, Disse B, Schröder-Babo W, et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Cin Immunol. 2011; 128: 308-14
|
|
|
|
|
|
30）Kerstjens HA, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Eng J Med. 2012; 367: 1198-207
|
|
|
|
|